William V. Bobo, MD

JCP
Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment
Original Research

June 27, 2022

The aim of this study was to develop and validate a categorical definition of “no meaningful benefit” from antidepressant treatment by equating percent change in scores on 3 common...
Carl Zhang, Sanya Virani, Taryn Mayes, et al
JCP
Original Research

January 11, 2022

Current practices for estimating the risk for mortality in teenage substance users rely heavily on clinical intuition. This study examined whether a positive urine drug screen in youth receiving...
Matej Markota, Paul E. Croarkin, William V. Bobo
JCP
Letter to the Editor

November 12, 2019

Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...
Balwinder Singh, William V. Bobo, Keith G. Rasmussen, et al
JCP
Original Research

April 26, 2017

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...
David Mischoulon, Richard C. Shelton, Lee Baer, et al
JCP
Original Research

January 27, 2016

Thilo Deckersbach, Andrew A. Nierenberg, Melvin G. McInnis, et al
JCP
Original Research

January 27, 2016

Andrew A. Nierenberg, Susan L. McElroy, Edward S. Friedman, et al
JCP
Original Research

July 12, 2011

Herbert Y. Meltzer, Stefania Bonaccorso, William V. Bobo, et al
JCP
Book Review

December 31, 2008

William V. Bobo
JCP
Original Research

May 11, 2008

Herbert Y. Meltzer, William V. Bobo, Isaac F. Nuamah, et al
JCP
Original Research

February 14, 2008

Herbert Y. Meltzer, William V. Bobo, Ajanta Roy, et al
PCC
Letter to the Editor

June 1, 2003

William V. Bobo, Kenneth F. More

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe